Dr. Kimball is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-7157Fax+1 410-328-6896
Education & Training
- University of Maryland Medical Center2009
- Sinai Hospital of BaltimoreResidency, Internal Medicine, 2006
- University of Maryland School of MedicineClass of 2002
Certifications & Licensure
- MD State Medical License 2009 - 2016
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
Publications & Presentations
PubMed
- 23 citationsPhase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.Ajay Major, Justin Kline, Theodore Karrison, Paul A. S. Fishkin, Amy S. Kimball
Haematologica. 2021-07-29 - 7 citationsPhase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.Wyndham H. Wilson, Tycel Phillips, Leslie Popplewell, Sven de Vos, Saurabh Chhabra
Leukemia & Lymphoma. 2021-04-15 - 2 citationsA phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.Melissa Alsina, Ola Landgren, Noopur Raje, Ruben Niesvizky, William I. Bensinger
American Journal of Hematology. 2021-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: